Oligomer-Opioid Agonist Conjugates
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 14 of these applications claim priority to application 61/227,399, filed Jul 21, 2009. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 8,440,687 | Oligomer-Opioid Agonist Conjugates In force · Medium confidence UsedRemaining | Nektar Therapeutics | In force | Medium confidence | ||
| US 8,569,343 | Oligomer-Opioid Agonist Conjugates In force · Medium confidence | Nektar Therapeutics | In force | Medium confidence | ||
| US 8,575,196 | Oligomer-Opioid Agonist Conjugates In force · Medium confidence | Nektar Therapeutics | In force | Medium confidence | ||
| US 8,946,285 | Oligomer-Opioid Agonist Conjugates In force · Medium confidence | Nektar Therapeutics | In force | Medium confidence | ||
| US 8,952,032 | Oligomer-Opioid Agonist Conjugates In force · Medium confidence | Nektar Therapeutics | In force | Medium confidence | ||
| US 9,233,167 | Oligomer-Opioid Agonist Conjugates In force · Medium confidence | Nektar Therapeutics | In force | Medium confidence | ||
| US 9,233,168 | Oligomer-Opioid Agonist Conjugates In force · Medium confidence | Nektar Therapeutics | In force | Medium confidence | ||
| US 9,458,166 | Oligomer-Opioid Agonist Conjugates In force · Medium confidence | Nektar Therapeutics | In force | Medium confidence | ||
| US 9,512,135 | Oligomer-Opioid Agonist Conjugates In force · Low confidence | Nektar Therapeutics | In force | Low confidence | ||
| US 9,827,239 | Oligomer-Opioid Agonist Conjugates In force · Medium confidence | Nektar Therapeutics | In force | Medium confidence | ||
| 7 more records in this group · Pro | ||||||
10 of 17 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 17, including 13 expiring within the 18 months from Nov 20, 2026.
14 of these are in force and held by Nektar Therapeutics.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.